Graceway Pharma Adds To Portfolio

Graceway Pharmaceuticals LLC, a portfolio company of GTCR Golder Rauner, has acquired the global license to an anti-proliferative agent from Gilead Sciences. The investigational molecule is designed to inhibit cellular DNA synthesis, leading to the induction of apoptosis. No financial terms were disclosed.

DealsNorth AmericaUSBriefs